Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Correction

Correction to: Co-relation with novel phosphorylation sites of IκBα and necroptosis in breast cancer cells

Authors: Sung Hoon Choi, Hee-Sub Yoon, Shin-Ae Yoo, Sung Ho Yun, Joo-Hee Park, Eun Hee Han, Sung-Gil Chi, Young-Ho Chung

Published in: BMC Cancer | Issue 1/2021

Login to get access

Excerpt

Correction to: BMC Cancer 21, 596 (2021) …
Literature
1.
Metadata
Title
Correction to: Co-relation with novel phosphorylation sites of IκBα and necroptosis in breast cancer cells
Authors
Sung Hoon Choi
Hee-Sub Yoon
Shin-Ae Yoo
Sung Ho Yun
Joo-Hee Park
Eun Hee Han
Sung-Gil Chi
Young-Ho Chung
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08919-w

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue

Research article

The implementation of colorectal cancer screening interventions in low-and middle-income countries: a scoping review

Research

Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

Research article

Prognostic value of the extent of lymphadenectomy for esophageal cancer-specific survival among T1 patients

Research article

Salvage surgery for patients with residual/persistent diseases after improper or insufficient treatment of oral squamous cell carcinoma: can we rectify these mistakes?

Research article

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Research article

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits